Navigation Links
Puma Biotechnology Announces Positive PB272 (Neratinib) Phase II Data at CTRC-AACR San Antonio Breast Cancer Symposium
Date:12/9/2011

d grade 3/4 diarrhea.  No patients in the neratinib arm of the trial and 14% of the patients in the lapatinib/capecitabine combination arm of the trial experienced grade 3/4 PPE.  The diarrhea with neratinib was reported to be transient and manageable with antidiarrheal medications. The efficacy results from the trial showed that for the 117 patients in the neratinib monotherapy arm of the trial, 2% of the patients experienced a complete response, 27% of the patients experienced a partial response and 15% of the patients experienced stable disease for greater than 6 months, which translates to an overall response rate of 29% and a clinical benefit rate of 44%.  For the 116 patients in the trial treated with the combination of lapatinib and capecitabine, 4% of the patients experienced a complete response, 36% of the patients experienced a partial response and 23% of the patients experienced stable disease for greater than 6 months, which translates to an overall response rate of 40% and a clinical benefit rate of 63%.  The median progression free survival (PFS) for patients in the neratinib monotherapy arm was 4.5 months and the median PFS for the patients who had received the combination of lapatinib and capecitabine was 6.8 months. 

Combined Inhibition of mTORC1 with Temsirolimus and HER2 with Neratinib:
A Phase I/II Study in Patients with Metastatic HER2-Amplified or Triple-Negative Breast Cancer

The Phase I/II clinical trial of PB272 given in combination with the chemotherapy drug temsirolimus was conducted at Memorial Sloan-Kettering Cancer Center.  The trial was sponsored by Pfizer and the Phase I results of this trial were previously presented last year.  The Phase II portion of the study, presented at this symposium, enrolled patients with either HER2+ metastatic breast cancer and disease progression on trastuzumab or with triple negative breast cancer.  Patients in the study received
'/>"/>

SOURCE Puma Biotechnology, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. The European Union Signs Grant Contract to Fund a 2 Million Euro Biotechnology Research Project Led by Hadassah College Jerusalem
2. Animal Biotechnology - Technologies, Markets and Companies
3. Puma Biotechnology Announces Completion of Private Placement
4. HUYA Bioscience International Builds Long-Term Relationship with Shenzhen Polytechnic School of Applied Chemistry and Biotechnology
5. Congressman Eric Cantor and Health Diagnostic Laboratory, Inc. Discuss Job Growth at Virginia BioTechnology Research Park
6. Industrial Biotechnology China News 1109 - Annual Subscription
7. Nanobiotechnology: Applications and Global Markets
8. Californias Industrial Biotechnology Workforce: Creating Jobs and Leading Innovation
9. Global Biotechnology Instrumentation Industry
10. Separation Systems for Commercial Biotechnology
11. TWi Biotechnology Successfully Completes Patient Recruitment for Phase IIb Trial of AC-201 for the Treatment of Type II Diabetes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/20/2014)... Oct. 20, 2014 Asterias Biotherapeutics, Inc. ... has signed a Notice of Grant Award (NGA) ... effective October 1, 2014.  The NGA provides for ... the release of additional grant funds pursuant to ... for clinical development of Asterias, product, AST-OPC1. The ...
(Date:10/20/2014)... , Oct. 20, 2014 PureTech , ... tackling big healthcare problems, announced today the closing ... with participation from Invesco Perpetual, a $120 Billion ... to drive PureTech,s existing pipeline forward and to ... has the scientific creativity to really go for ...
(Date:10/19/2014)... The Latin American hardware encryption display market report ... analysis and forecast of revenue. This market was valued ... reach $2,366.8 million by 2018, at a CAGR of ... TOC of the Latin American hardware encryption market report ... It also provides a glimpse of the segmentation of ...
(Date:10/19/2014)... The Asian Automatic patient billing report defines and ... of revenue. The Automatic patient billing market in Asia ... 2018, at a developing CAGR of 7.2% from 2013 ... Asian Automatic patient billing market, to get an idea ... glimpse of the segmentation of this market in the ...
Breaking Biology Technology:Asterias Biotherapeutics Announces Notice of Grant Award with CIRM for Phase 1/2a Clinical Trial of AST-OPC1 in Complete Cervical Spinal Cord Injury 2Asterias Biotherapeutics Announces Notice of Grant Award with CIRM for Phase 1/2a Clinical Trial of AST-OPC1 in Complete Cervical Spinal Cord Injury 3Asterias Biotherapeutics Announces Notice of Grant Award with CIRM for Phase 1/2a Clinical Trial of AST-OPC1 in Complete Cervical Spinal Cord Injury 4PureTech Announces Expansion with Oversubscribed $55M Funding Round 2PureTech Announces Expansion with Oversubscribed $55M Funding Round 3PureTech Announces Expansion with Oversubscribed $55M Funding Round 4PureTech Announces Expansion with Oversubscribed $55M Funding Round 5PureTech Announces Expansion with Oversubscribed $55M Funding Round 6The Latin American hardware encryption display market is expected to reach $2,366.8 million by 2018 - New Report by MicroMarket Monitor 2The Latin American hardware encryption display market is expected to reach $2,366.8 million by 2018 - New Report by MicroMarket Monitor 3The Asian Automatic patient billing market is estimated to grow to around $463.9 million by 2018 - New Report by MicroMarket Monitor 2The Asian Automatic patient billing market is estimated to grow to around $463.9 million by 2018 - New Report by MicroMarket Monitor 3
... HUNTINGTON BEACH, California and AMSTERDAM, September ... today announced the,successful closing of a US $23 million ... undisclosed family investment firm that provided,approximately half of the ... of US $1 million each, while the remaining,capital was ...
... , ATLANTA, Sept. 22 The International ... Rose Associates has joined its global network. IESF is the ... welcome Sanford Rose Associates (SRA) as one of its global ... offices primarily located throughout the USA will considerably enhance IESF,s ...
... , , PRINCETON, N.J., Sept. 22 ... clinical development services to innovative pharmaceutical, biotechnology, generic drug ... Brennan has joined the Company as general counsel. , ... have Chris join the PharmaNet Development Group management team," ...
Cached Biology Technology:Agendia Raises US $23 Million in Series E Financing 2Sanford Rose Associates Joins the International Executive Search Federation 2Christopher Brennan Joins PharmaNet Development Group as General Counsel 2
(Date:10/16/2014)... Melbourne researchers have challenged conventional thinking on how the ... new mechanism for how bowel cancer starts. , The ... maintaining and regenerating the ,crypts, that are a feature ... are involved in bowel cancer development, a controversial finding ... existence. , Using 3D imaging technologies, Dr Chin Wee ...
(Date:10/16/2014)... , October 16, 2014 NXT-ID, Inc. (NASDAQ: ... "Company"), a biometric authentication company focused on the growing ... edge technologies including Wocket™, the Smart Wallet, at the ... FiRe is a leading global conference on the intersection ... by Mark Anderson , founder and publisher of ...
(Date:10/15/2014)... has admitted Johannes Gutenberg University Mainz (JGU) as ... hub continues to maintain a significant nationwide standing ... "The acceptance of Johannes Gutenberg University Mainz as ... milestone in the national and international competition for ... of Rhineland-Palatinate can be proud that Mainz University ...
Breaking Biology News(10 mins):Cryptic clues drive new theory of bowel cancer development 2NXT-ID Inc. to Present at 13th Annual FiRe Conference 2NXT-ID Inc. to Present at 13th Annual FiRe Conference 3Johannes Gutenberg University Mainz joins Germany's Gauss-Allianz as a full member 2Johannes Gutenberg University Mainz joins Germany's Gauss-Allianz as a full member 3
... 2004, Washington University in St. Lous researcher Jianmin Cui was ... channel his lab had been studying for five years. ... a large family whose members suffered from epilepsy, sudden attacks ... and paroxysmal dyskinesia (GEPD). By analyzing the DNA of ...
... attacks in the United States are fostering development of ... to protect people against the potentially deadly bacteria in ... sweeping overview of scientific research on medical technology to ... Journal of Medicinal Chemistry . In ...
... are reporting that particle size affects the toxicity of zinc ... 100 nanometers are slightly more toxic to colon cells than ... equivalent amounts of soluble zinc, and direct particle to cell ... in ACS, Chemical Research in Toxicology , a monthly ...
Cached Biology News:Solving the puzzle of the BK ion channel 2Solving the puzzle of the BK ion channel 3Solving the puzzle of the BK ion channel 4Solving the puzzle of the BK ion channel 5New medical weapons to protect against anthrax attacks 2
...
DTT 50 l...
...
Chicken polyclonal to YebU ( Abpromise for all tested applications). Antigen: Synthetic peptide, corresponding to amino acids 196-244 of E. coli YebU....
Biology Products: